Blood biomarkers for Alzheimer’s disease in clinical practice and trials
dc.contributor.author | Hansson, Oskar | |
dc.contributor.author | Blennow, Kaj | |
dc.contributor.author | Zetterberg, Henrik | |
dc.contributor.author | Dage, Jeffrey | |
dc.contributor.department | Neurology, School of Medicine | |
dc.date.accessioned | 2024-06-24T14:02:02Z | |
dc.date.available | 2024-06-24T14:02:02Z | |
dc.date.issued | 2023 | |
dc.description.abstract | Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the recent development of anti-amyloid-β (Aβ) immunotherapies. Several assays for measuring phosphorylated tau (p-tau) in plasma exhibit high diagnostic accuracy in distinguishing AD from all other neurodegenerative diseases in patients with cognitive impairment. Prognostic models based on plasma p-tau levels can also predict future development of AD dementia in patients with mild cognitive complaints. The use of such high-performing plasma p-tau assays in the clinical practice of specialist memory clinics would reduce the need for more costly investigations involving cerebrospinal fluid samples or positron emission tomography. Indeed, blood-based biomarkers already facilitate identification of individuals with pre-symptomatic AD in the context of clinical trials. Longitudinal measurements of such biomarkers will also improve the detection of relevant disease-modifying effects of new drugs or lifestyle interventions. | |
dc.eprint.version | Author's manuscript | |
dc.identifier.citation | Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer's disease in clinical practice and trials. Nat Aging. 2023;3(5):506-519. doi:10.1038/s43587-023-00403-3 | |
dc.identifier.uri | https://hdl.handle.net/1805/41815 | |
dc.language.iso | en_US | |
dc.publisher | Springer Nature | |
dc.relation.isversionof | 10.1038/s43587-023-00403-3 | |
dc.relation.journal | Nature Aging | |
dc.rights | Publisher Policy | |
dc.source | PMC | |
dc.subject | Alzheimer disease | |
dc.subject | Amyloid beta-peptides | |
dc.subject | Cognitive dysfunction | |
dc.title | Blood biomarkers for Alzheimer’s disease in clinical practice and trials | |
dc.type | Article |